Ensol Biosciences Inc. (XKON: 140610)
South Korea
· Delayed Price · Currency is KRW
6,220.00
-240.00 (-3.72%)
Sep 10, 2024, 9:00 AM KST
Ensol Biosciences Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| TTM
| FY 2017 | FY 2016 | FY 2015 |
| Dec '17 Dec 31, 2017 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 | Dec '15 Dec 31, 2015 |
| Net Income | -5,404 | -5,404 | -6,067 | -6,128 |
| Depreciation & Amortization | 398.38 | 398.38 | 406.16 | 344.91 |
| Loss (Gain) From Sale of Assets | -1.48 | -1.48 | - | - |
| Asset Writedown & Restructuring Costs | 313.2 | 313.2 | 1,480 | - |
| Loss (Gain) From Sale of Investments | - | - | - | 19.93 |
| Stock-Based Compensation | 254.06 | 254.06 | 347.71 | 47.76 |
| Provision & Write-off of Bad Debts | 347.8 | 347.8 | - | - |
| Other Operating Activities | 291.55 | 291.55 | 150.59 | 3,835 |
| Change in Accounts Receivable | -396.41 | -396.41 | 26.28 | 63.05 |
| Change in Income Taxes | -4.23 | -4.23 | 1.36 | -7.88 |
| Change in Other Net Operating Assets | -452.27 | -452.27 | 223.5 | -98.91 |
| Operating Cash Flow | -4,653 | -4,653 | -3,432 | -1,924 |
| Capital Expenditures | -142.78 | -142.78 | -162.36 | -629.68 |
| Sale of Property, Plant & Equipment | 1.48 | 1.48 | - | - |
| Cash Acquisitions | - | - | -1,488 | - |
| Sale (Purchase) of Intangibles | -50.98 | -50.98 | -187.65 | -148.09 |
| Investment in Securities | 2,616 | 2,616 | -2,999 | -1,520 |
| Other Investing Activities | 0 | 0 | - | - |
| Investing Cash Flow | 2,424 | 2,424 | -4,837 | -2,298 |
| Short-Term Debt Issued | 30 | 30 | - | 2,050 |
| Total Debt Issued | 30 | 30 | - | 2,050 |
| Short-Term Debt Repaid | - | - | -1,680 | -370 |
| Long-Term Debt Repaid | - | - | -180 | -3,090 |
| Total Debt Repaid | - | - | -1,860 | -3,460 |
| Net Debt Issued (Repaid) | 30 | 30 | -1,860 | -1,410 |
| Issuance of Common Stock | - | - | 6,996 | 5,599 |
| Other Financing Activities | - | - | -10.8 | - |
| Financing Cash Flow | 30 | 30 | 5,125 | 10,187 |
| Miscellaneous Cash Flow Adjustments | -0 | -0 | - | - |
| Net Cash Flow | -2,200 | -2,200 | -3,144 | 5,965 |
| Free Cash Flow | -4,796 | -4,796 | -3,595 | -2,554 |
| Free Cash Flow Margin | -892.34% | -892.34% | -2066.14% | -1264.31% |
| Free Cash Flow Per Share | -571.56 | -571.56 | -436.04 | -380.06 |
| Cash Interest Paid | 1.9 | 1.9 | 41.44 | 217.25 |
| Levered Free Cash Flow | -3,263 | -3,263 | -2,328 | - |
| Unlevered Free Cash Flow | -3,261 | -3,261 | -2,304 | - |
| Change in Net Working Capital | 293.18 | 293.18 | -321.61 | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.